GlassScriptPhysician profile
Catrina C Bubier
NPI 1699854869
$4,283.62
in general payments reported to CMS, 2019-2025
36 companies · $621 in 2025
The $621 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $215 · 2021: $517 · 2022: $908 · 2023: $968 · 2024: $530 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.99 |
| Education | $154.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $983.56 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Bayer Healthcare Pharmaceuticals INC. | $506.66 | 2019-2025 | |
| Hologic Sales and Service, LLC | $399.71 | 2019-2025 | Acessa Provu System, Omni Hysteroscope, Myosure Tissue Removal Device |
| Exeltis, USA INC. | $227.51 | 2019-2025 | Slynd |
| Organon LLC | $227.41 | 2021-2025 | Nexplanon |
| Coopersurgical, INC. | $185.01 | 2019-2023 | Paragard T 380a |
| Avanos Medical | $173.32 | 2019-2023 | On-Q* Pump and Accessories |
| Avion Pharmaceuticals | $141.40 | 2019-2021 | |
| Medtronic, INC. | $137.18 | 2024 | Abre |
| Mayne Pharma Commercial LLC | $137.10 | 2022-2025 | |
| Medical Device Business Services, INC. | $137.01 | 2025 | Stratafix |
| Merck Sharp & Dohme LLC | $129.99 | 2020-2024 | Gardasil, Gardasil 9 |
| Astellas Pharma US INC | $125.84 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $117.57 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $74.39 | 2023-2025 | Myfembree, Gemtesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $68.43 | 2024-2025 | Cologuard Collection Kit |
| Roche Diagnostics Corporation | $65.45 | 2019-2021 | |
| Therapeuticsmd, INC. | $57.94 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $57.57 | 2019 | |
| Sage Therapeutics, LLC | $41.36 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $30.67 | 2023 | Accrufer |
| C. R. Bard, INC. & Subsidiaries | $29.14 | 2022-2024 | Bd Onclarity |
| Glaxosmithkline, LLC. | $23.46 | 2020 | |
| Supernus Pharmaceuticals, INC. | $23.19 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $20.01 | 2019 | |
| Ascend Therapeutics US, LLC | $18.33 | 2021 | |
| Mimedx Group, INC. | $17.48 | 2025 | |
| Meditrina | $17.42 | 2024 | |
| Evofem Biosciences, INC. | $16.86 | 2021 | |
| Ibsa Pharma INC. | $16.03 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.13 | 2023 | Quviviq |
| Baudax Bio INC. | $14.42 | 2020 | |
| Agile Therapeutics, INC. | $13.14 | 2021 | |
| Minerva Surgical, INC | $11.50 | 2019 | |
| Lupin INC. | $11.50 | 2021 | |
| Covidien LP | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catrina Bubier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.